Skip to main content


Table 4 IC50 values of rhArg1 versus rhArg1-peg5,000 mw for human hepatocellular carcinomas in vitro.

From: Pegylated derivatives of recombinant human arginase (rhArg1) for sustained in vivo activity in cancer therapy: preparation, characterization and analysis of their pharmacodynamics in vivo and in vitro and action upon hepatocellular carcinoma cell (HCC)

  rhArg1 (U/ml) rhArg1-peg5,000 mw (U/ml)
HepG2 0.18 ± 0.06 0.22 ± 0.03
Hep3B 0.07 ± 0.03 0.10 ± 0.04
  1. HepG2 and Hep3B were incubated in arginine-containing DMEM medium supplemented with 10% FBS with rhArg or rhArg1-peg5,000 mw (0–100 U/ml) for 72 h at 37°C/5% CO2. IC50 values were calculated as the concentration of native rhArg1 or pegylated rhArg1 which inhibited 50% cell growth. The experiments were repeated three times.